anti-inflammatory cytokines
anti-inflammatory cytokines
Overview
Anti-inflammatory cytokines are a class of immunoregulatory signaling proteins that function to dampen, resolve, or counterbalance inflammatory responses initiated by pro-inflammatory cytokines such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). The most extensively studied member of this group is interleukin-10 (IL-10), alongside transforming growth factor-beta (TGF-β), interleukin-4 (IL-4), interleukin-13, and interleukin-21. These molecules operate through a network of receptor-mediated signaling cascades — including the JAK2/STAT3 signaling pathway and PI3K/Akt signaling pathway — to modulate immune cell activation, macrophage polarization, and tissue repair. Their physiological roles span the resolution of acute inflammation, maintenance of immune homeostasis, and protection of tissues from immune-mediated damage across virtually every organ system.
The balance between pro-inflammatory and anti-inflammatory cytokines is a critical determinant of disease outcome in a broad spectrum of conditions, including autoimmune disorders, metabolic diseases, neurodegenerative conditions, and cancer. Dysregulation of this balance — particularly a deficiency in anti-inflammatory cytokine signaling — is associated with chronic inflammatory pathologies such as inflammatory bowel disease, rheumatoid arthritis, psoriatic arthritis, and cardiovascular disease. As a result, strategies to restore or amplify anti-inflammatory cytokine activity, whether through exogenous delivery, pharmacological induction, or cellular reprogramming, represent a major focus of contemporary biomedical research.
Focus of Latest Publications
Recent publications have examined anti-inflammatory cytokines, especially interleukin-10 (IL-10), in diverse inflammatory and regenerative settings. In severe traumatic brain injury, early inflammatory mediator profiling in plasma and cerebrospinal fluid showed that IL-10 was consistently elevated alongside IL-6 and IL-8 during the first week after injury, with particularly marked compartmentalized changes in cerebrospinal fluid. In the same study, IL-10 measurements were compared across electrochemiluminescence and proximity extension assay platforms, and the two methods showed strong correlation for IL-10 but limited interchangeability overall.
Several studies linked IL-10 to therapeutic modulation of inflammation. In a mouse model of repetitive mild traumatic brain injury, intranasal mRNA-loaded lipid nanoparticles co-delivering brain-derived neurotrophic factor and IL-10 reduced neuroinflammation, inhibited neuronal death, and improved cognition. In acute lung injury, a lung-targeted lipid nanoparticle platform delivered IL-10 mRNA and significantly reduced the inflammatory response. In myocardial infarction, a spatiotemporally orchestrated microneedle patch used adeno-associated virus-mediated IL-10 delivery during the remodeling phase to suppress aberrant fibroblast activation and limit fibrosis, complementing an early magnesium-loaded nanoparticle module aimed at the inflammatory phase.
IL-10 also appeared in studies of tissue repair and immune regulation. In diabetic and infected wound models, biomaterial-based hydrogels promoted healing in part by increasing IL-10 and shifting macrophages toward reparative phenotypes, while reducing pro-inflammatory mediators such as TNF-α and IL-6. A dual-crosslinked hydrogel for diabetic chronic wounds downregulated TNF-α and IL-6 and upregulated IL-10, and a conductive exosome-loaded hydrogel with electrical stimulation similarly upregulated IL-10 to drive M2 polarization and alleviate inflammation. In women with breast cancer receiving chemotherapy, strength training was associated with changes in serum cytokines including IL-10, although no significant group-by-time interaction was reported and the clinical significance remained uncertain.
Other publications used IL-10 as a biomarker or part of broader cytokine profiling. In monozygotic twins discordant for pain-related temporomandibular disorder, plasma IL-10 was measured together with IL-6, and the IL-6/IL-10 ratio differed within twin pairs, contributing to an inflammatory-oxidative profile associated with pain. In cervical cancer progression, IL-10 expression was evaluated alongside TNF-α, IL-6, IL-8, and VEGF across weight categories. In vitreoretinal lymphoma, elevated intraocular IL-10 was noted as an established biomarker, and the first vitreous detection of IL-16 was reported as a potential additional indicator.